This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is ALPS O'Shares U.S. Quality Dividend ETF (OUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for OUSA
Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PFM
Pharma Stock Roundup: JNJ Beats on Q1 Earnings, MRK to Buy RXDX & Other Updates
by Kinjel Shah
J&J (JNJ) beats earnings and sales estimates for the first quarter. Merck (MRK) offers to buy Prometheus Biosciences (RXDX).
Johnson & Johnson (JNJ) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Legend (LEGN) Stock Up 20% on Data Leak From Blood Cancer Study
by Zacks Equity Research
Leaked data from Legend Biotech's (LEGN) phase III study of the blood cancer drug, Carvykti, shows a 74% reduction in risk of death or tumor progression. Stock jumps 20% following the news.
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ETFs to Buy on Solid Q1 JNJ Earnings Results
by Sweta Killa
Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It topped the revenue estimate as well as lifted the full-year outlook.
Stock Market News for Apr 19, 2023
by Zacks Equity Research
U.S. stocks finished little changed on Tuesday as investors digested a slew of corporate earnings reports from big banks and blue chip companies and also tried to gauge the future interest rate hike path.
Johnson and Johnson Beats Estimates and Raises Guidance
by Ethan Feller
Johnson and Johnson JNJ reported Q1 2023 earnings on Tuesday, April 18 before the market opened
Building Permits Declined in March
by Zacks Equity Research
Building Permits Declined in March
J&J (JNJ) Q1 Earnings & Sales Top, 2023 View Up, Stock Rises
by Zacks Equity Research
J&J (JNJ) beats estimates for first-quarter earnings and sales. It raises full-year sales and earnings guidance.
Housing Data Muted but Decent; JNJ and BAC Beat on Q1 Earnings
by Mark Vickery
Fresh Q1 earnings reports from major household firms join housing data from last month ahead of today's open.
Johnson & Johnson (JNJ) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson (JNJ) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 6.77% and 5.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Q1 Earnings Season Kicks Off Better than Expected
by Mark Vickery
We've got a long way to go, but some key regional banks have already reported and offered some relief to market participants.
Will Any Banks Show Signs of Stress? Global Week Ahead
by John Blank
In terms of macro data, the first snapshot of business activity in April (the PMIs) could provide a sense of how much pain the turmoil in the banking sector has inflicted on the world economy.
Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?
by Zacks Equity Research
In J&J's (JNJ) Pharma segment, its oncology drug, Darzalex as well as a psoriasis treatment, Stelara is likely to have driven sales growth in the first quarter
Lilly's (LLY) Ulcerative Colitis Candidate Gets CRL from FDA
by Zacks Equity Research
The FDA rejects Eli Lilly's (LLY) regulatory filing seeking approval for mirikizumab to treat ulcerative colitis indication, citing issues related to the drug's proposed manufacturing.
J&J (JNJ) to Initiate Q1 Earnings Season for Pharma Sector
by Zacks Equity Research
Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and Stelara. In the MedTech segment, continued recovery in worldwide procedure volume should drive sales.
Will Q1 Earnings Fuel a Rally in Dow ETF?
by Sweta Killa
As the index is closely tied to the cyclical sectors, the banking turmoil hit hard the Dow last month. Recession fears have added to the woes.
Is Vanguard Dividend Appreciation ETF (VIG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VIG
Analysts Estimate Johnson & Johnson (JNJ) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $164.32, marking a -0.5% move from the previous day.
AbbVie (ABBV), J&J to Withdraw 2 Blood Cancer Nods for Imbruvica
by Zacks Equity Research
AbbVie (ABBV)/J&J's (JNJ) decision to withdraw the FDA's accelerated approval for Imbruvica in two blood cancer treatments is based on confirmatory studies data that do not support full approval.
3 Sector ETFs to Play as Recession Fears Are on the Rise
by Yashwardhan Jain
With recession fears on the rise, look into some sectors that can shield from market volatility.